title: Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide.
abstract: BACKGROUND
  Low- to intermediate-grade chondrosarcoma is usually a slow-growing and highly chemotherapyresistant tumor type.
  
  
  METHODS
  The 76-year-old female patient presented with low- to intermediate-grade chondrosarcoma of the distal phalanx of the right thumb in 1993 and was treated with an excision of the carpometacarpal joint. Approximately 10 years later, the patient presented with recurrent local disease at the trapezoid bone, which was resected. Eight months later she presented with local recurrence at the carpal joint and lung metastases. Subsequently she was treated chemotherapeutically with pegylated liposomal doxorubicin as part of a clinical trial. Due to tumor progression after 2 cycles, she was switched to oral trofosfamide (150 mg daily). A follow-up CT scan after 8 months demonstrated a partial remission that was confirmed by a second scan after 9 months of treatment. The treatment was well tolerated. After 18 months of continued treatment, she was still in remission and on trofosfamide.
  
  
  CONCLUSIONS
  Trofosfamide at a daily dose of 150 mg may be effective in low- to intermediate-grade chondrosarcoma.
authors: Department of General Medical Oncology and Leuven Cancer Institute, Belgium.
authors: Philip R
authors: PR
authors: Debruyne
authors: Herlinde
authors: H
authors: Dumez
authors: Wim
authors: W
authors: Demey
authors: Lutgart
authors: L
authors: Gillis
authors: Raf
authors: R
authors: Sciot
authors: Patrick
authors: P
authors: Schöffski
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D052737:Carpometacarpal Joints / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002813:Chondrosarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D013933:Thumb / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D014057:Tomography, X-Ray Computed
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; C003726:trofosfamide